Evolus: US FDA validates troubled CMO site, but rejects BOTOX alternative

By Flora Southey

- Last updated on GMT

Getty/ComicSans
Getty/ComicSans
Evolus says its South Korean CMO has successfully addressed GMP violations, but US FDA is yet to approve the firm’s alternative to Allergan’s BOTOX.

The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) to Evolus, rejecting its biologics license application (BLA) for DWP-450 (prabotulinumtoxinA) for chemistry, manufacturing, and controls (CMC) deficiencies.

The candidate – an alternative to Allergan’s onabotulinumtoxinA (BOTOX) – is designed to temporarily improve the appearance of moderate to severe ‘frown lines’, also known as glabellar lines.

“We believe the CMC questions are very reasonable, since over half of the questions have already been completed and most were already in progress, which is why we believe we can respond to the FDA very quickly within the 90-day time frame,” ​a spokesperson told us.

“We now have the line of sight necessary to build our commercial infrastructure.

“We look forward to working closely with the FDA and remain committed to bringing DWP-450 to market by spring 2019,” ​the spokesperson added.

US FDA validates troubled CMO site

Evolus was however pleased to announce its contract manufacturing organisation’s (CMO’s) troubled facility had received FDA approval.

Last year, ten manufacturing violations​ landed Daewoong Pharmaceutical a Form 483​ for its Gyeonggi-do-based site in South Korea – a facility purposely built to make DWP-450.

According to Evolus, the FDA has since issued an establishment inspection report (EIR) to Daewoong confirming the favourable completion of a pre-approval inspection.

Evolus says the Daewoong facility will support commercial production following the anticipated approval of its lead candidate.

“We appreciate our continued relationship with Daewoong and the work of our entire team as we continue to advance our BLA submission towards expected approval,” ​the Evolus spokesperson told us.

Related news

Show more

Related products

eBook: mRNA prospects and scale-up solutions

eBook: mRNA prospects and scale-up solutions

Content provided by Thermo Fisher Scientific - Biosciences | 22-Mar-2023 | Insight Guide

This mRNA eBook was created by Thermo Fisher Scientific, in collaboration with Genetic Engineering & Biotechnology News (GEN), to provide you with...

Impurity profiling and analysis of TheraPure GMP nucleotides

Impurity profiling and analysis of TheraPure GMP nucleotides

Content provided by Thermo Fisher Scientific - Biosciences | 22-Mar-2023 | White Paper

Nucleoside triphosphates (NTPs) are vital components of emerging RNA therapeutics and vaccines. Controlling impurities that may be present in them while...

Related suppliers

Follow us

Products

View more

Webinars